TerraPower
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Seed | ||
N/A | Series A | ||
* | $35.0m | Series B | |
$10.6m Valuation: $10.6m | Series B | ||
N/A Valuation: $225m | Series C | ||
N/A Valuation: $641m | Series D | ||
N/A Valuation: $736m | Series E | ||
* | $80.0m | Grant | |
* | $8.5m | Grant | |
* | $750m | Late VC | |
* | $80.0m Valuation: $3.8b | Late VC | |
Total Funding | €876m |
Recent News about TerraPower
EditTerraPower is a pioneering nuclear innovation company focused on developing advanced nuclear reactors to provide carbon-free energy solutions. The company operates in the energy sector, targeting both the power generation market and the medical field through the extraction of radioisotopes for cancer treatment. TerraPower's core business model revolves around the research, development, and commercialization of next-generation nuclear technologies, including the Traveling Wave Reactor, Molten Chloride Fast Reactor, and sodium fast reactor technologies. These innovations aim to meet the growing global demand for clean energy while also addressing critical medical needs. TerraPower generates revenue through partnerships, technology licensing, and supply agreements, such as its collaboration with Radiopharm for Actinium 225. The company serves a diverse client base, including energy utilities, government agencies, and medical institutions, and operates primarily in the United States with international collaborations.
Keywords: nuclear innovation, carbon-free energy, advanced reactors, medical isotopes, Traveling Wave Reactor, Molten Chloride Fast Reactor, sodium fast reactor, clean energy, cancer treatment, technology licensing.